Thromb Haemost 2005; 93(03): 481-487
DOI: 10.1160/TH04-10-0650
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Clinical phenotypes and factor VII genotype in congenital factor VII deficiency

Guglielmo Mariani
1   Dipartimento di Medicina Interna e Sanità Pubblica, Università de L’Aquila, Italy
,
Falko H. Herrmann
2   Institut für Humangenetik, E. M. Arndt Universität, Greifswald, Germany
,
Alberto Dolce
3   Istituto Nazionale di Statistica, Rome, Italy
,
Angelika Batorova
4   Haemophilia Centre, Bratislava, Slovak Republic
,
Daniela Etro
5   Dipartimento di Biochimica e Biologia Molecolare, Università di Ferrara, Italy
,
Flora Peyvandi
6   IRCCS Ospedale Maggiore di Milano, Angelo Bianchi Bonomi, University of Milan, Italy
,
Karin Wulff
2   Institut für Humangenetik, E. M. Arndt Universität, Greifswald, Germany
,
Jean F. Schved
7   Laboratoire Central d’Hématologie, CHU Montpellier, France
,
Günter Auerswald
8   Kinderklinik, Zentral Kranken Hauses, Bremen, Germany,
,
Jorgen Ingerslev
9   Hemophilia Centre, Department of Clinical Biochemistry, University Hospital of Aarhus/Skejby, Denmark
,
Francesco Bernardi
5   Dipartimento di Biochimica e Biologia Molecolare, Università di Ferrara, Italy
,
for the International Factor VII Deficiency Study Group (see appendix)› Author Affiliations

Grant support Telethon Italy (grant GGP02182); University of Palermo and University of Ferrara Research Faculty Grants; unrestricted grant from Novonordisk (Bagsværd, Denmark).
Further Information

Publication History

Received 06 October 2004

Accepted after revision 28 February 2004

Publication Date:
14 December 2017 (online)

Preview

Summary

To investigate the relationship between clinical phenotype, clotting activity (FVIIc) and FVII genotype, a multi-center study of factor VII (FVII) congenital deficiency with centralized genotyping and specific functional assays was carried out. FVII mutations characterized in patients (n=313) were extremely heterogeneous (103 different, 22 novel). Clinical phenotypes ranged from asymptomatic condition, including 15 homozygotes and 14 double heterozygotes, to patients with a severe disease char-acterized by life-threatening and disabling symptoms (CNS, GI bleeding and hemarthrosis) strongly associated with an early age of presentation. Based on type and number of symptoms we classified 90 'severe' (median FVIIc 1.4%, IQR [Interquartile Range] 0.9–3.8), 83 'moderate' (FVIIc 3%, IQR 1–21.7), and 140 'mild' bleeders (FVIIc 14%, IQR 3–31). The significantly different FVIIc levels, and the decreasing prevalence of homozygotes or double heterozygotes among severe (98%), moderate (84%) and mild (56%) bleeders, further support our classification. The excess of females among moderate bleeders (female/male ratio =2.6) is attributable to menorrhagia. There was no evidence for modulation of clinical features by frequent functional polymorphisms. Homozygotes for the same mutation (Ala294Val; 11125del C) with similar FVIIc and FXa generation levels, showed striking differences in clinical phenotypes. Our study depicts the ample clinical picture of this rare disorder, proposes a severity classification and provides arguments for the early management of the disease in the severe cases. Genotype-phenotype relationships indicate the presence of major environmental and/or extragenic components modulating expressivity of FVII deficiency.